Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
You may also be interested in...
European Countries Flags Four Medicines For Joint HTA Evaluation
Drugs for treating Duchenne muscular dystrophy and amyotrophic lateral sclerosis are among the products that the European cross-country coalition BeNeLuxA thinks would be suitable for a joint health technology evaluation.
Ireland, Belgium And The Netherlands Withdraw From Libmeldy Gene Therapy Pricing Talks
The BeNeLuxA medicines access coalition has terminated pricing talks with Orchard over its gene therapy Libmeldy.
Europe: Cross-Country HTA of Gene Therapy Libmeldy Calls For Price Cut
Joint price negotiations for Orchard’s gene therapy Libmeldy could follow outcome of multi-country health technology assessment.